Braxia Scientific (BRAX) Developing Ketamine Treatments of the Future
Braxia Scientific Corp (CNSX:BRAX, OTCMKTS:BRAXF) is a medical research psychedelics company that owns a global network of clinics providing innovative ketamine treatments for persons with depression and related disorders. The company successfully expanded its network of multidisciplinary clinics to four earlier this year, with one of the very few private intravenous ketamine treatment clinics approved in Canada.
Braxia Scientific is also developing psychedelic drug formulations related to Ketamine and Esketamine. The company’s clinics are advancing multiple research and development studies and conducting clinical trials with psychedelic derivatives and IP-capable delivery methods.
The Company recorded revenues of $1,008,372 and gross margins of was approximately 17.3% as a percentage of total revenue in the last year. Revenues consisted primarily of sales revenue from the administering of ketamine infusion treatments at the company’s clinics.
Braxia expects to add to its clinic footprint in 2021 and continue carrying out several clinical trials. The attractive point for investors is the fact Braxia’s clinical trials will mostly be funded by third parties.